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The underlying mechanism of necroptosis in relation to cancer is
still unclear. Here, MYC, a potent oncogene, is an antinecroptotic
factor that directly suppresses the formation of the RIPK1–RIPK3
complex. Gene set enrichment analyses reveal that the MYC path-
way is the most prominently down-regulated signaling pathway
during necroptosis. Depletion or deletion of MYC promotes the
RIPK1–RIPK3 interaction, thereby stabilizing the RIPK1 and RIPK3
proteins and facilitating necroptosis. Interestingly, MYC binds to
RIPK3 in the cytoplasm and inhibits the interaction between
RIPK1 and RIPK3 in vitro. Furthermore, MYC-nick, a truncated
form that is mainly localized in the cytoplasm, prevented TNF-
induced necroptosis. Finally, down-regulation of MYC enhances
necroptosis in leukemia cells and suppresses tumor growth in a
xenograft model upon treatment with birinapant and emricasan.
MYC-mediated suppression of necroptosis is a mechanism of nec-
roptosis resistance in cancer, and approaches targeting MYC to
induce necroptosis represent an attractive therapeutic strategy
for cancer.
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Necroptosis is a programmed cell death pathway that is exe-cuted by the necrosome complex, which comprises receptor-
interacting protein kinases such as RIPK1 and RIPK3 (1–4). The
binding of TNF-α to TNF receptor 1 induces the activation of
RIPK3, which phosphorylates downstream mixed lineage kinase
domain-like protein (MLKL) (5–7). Phosphorylated MLKL
forms an oligomer and functions as a necroptosis executioner by
directly or indirectly disrupting plasma membrane integrity (8–
12). While the molecular mechanisms and physiological rele-
vance of necroptosis have been relatively well studied, little is
known about the contributions of necroptosis to tumorigenesis
and tumor progression (13–19).
Numerous studies have focused on the effect of necroptosis
on cancer treatment (20). Various anticancer agents, such as
death receptor ligands (TNF-α and TRAIL [tumor necrosis
factor-related apoptosis-inducing ligand]), caspase inhibitors
(zVAD-fmk and IDN-6556), Smac mimetics, staurosporine, 5-
fluorouracil, cisplatin, and FTY720, have been reported to
induce necroptotic cell death in cancer cells, although the
precise mechanisms and target molecules involved in the ex-
ecution of necroptosis require further examination (21, 22).
However, cancer cells also possess or can develop strategies to
escape necroptosis and apoptosis to survive under necroptosis-
inducing conditions (23–25). Therefore, elucidation of the
interplay between necroptosis and cancer cells would provide
insights into necroptosis-targeted cancer treatment.
The transcription factor MYC is a representative oncoprotein
that regulates various cellular processes, including cell prolifer-
ation, differentiation, inflammation, and metabolism (26–28).
Here, we demonstrate that MYC functions as an antinecroptotic
factor by inhibiting the RIPK1 and RIPK3 interaction, indicating
that cancer cells may use MYC overexpression as a strategy to
escape necroptotic cell death. These observations highlight the
dynamic interplay between necroptosis and the oncoprotein
MYC, suggesting a prospective therapeutic strategy.
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Results
TNF-α–Dependent Necroptosis Induces MYC Down-Regulation. We
first searched for the pathways that are affected by necroptosis
by performing an RNA-sequencing analysis of HT-29 human
colon cancer cells followed by a gene set enrichment analysis
(GSEA) to identify new signaling pathways associated with
necroptosis. For these analyses, HT-29 cells were treated with
TNF-α, the cIAP inhibitor BV6, and the pan-caspase inhibitor
zVAD-fmk (TBZ) for 4 h to induce necroptosis, as previously
reported (2, 29, 30). MLKL-depleted HT-29 cells were also used
to prevent necroptotic cell death and monitor the long-term
effects of necroptosis (5). Consistent with previous studies, tar-
get gene sets of inflammatory transcription factors were enriched
in HT-29 cells treated with TBZ compared to the cells adminis-
tered the control treatment (SI Appendix, Fig. S1 A and B)
(31–33). Interestingly, target gene sets for MYC/MAX were sig-
nificantly down-regulated in cells treated for 4 h and 12 h (SI Ap-
pendix, Fig. S1 A and B). Necroptotic cell gene signatures showed
inverse correlations with various MYC-related gene sets (SI Ap-
pendix, Fig. S1C). These changes were also observed in MLKL-
depleted cells subjected to necroptotic stress for 5 h, further
suggesting that necroptosis signaling might induce downstream
changes in MYC transcription independent of MLKL-mediated
necroptotic cell death (SI Appendix, Fig. S1 D and E). When the
GSEA data were further confirmed by directly measuring the
levels of various proteins in cells under necroptotic stimulation,
the levels of inflammatory signaling markers, including IKK,
p100/p52 (noncanonical NF-κB), JNK, c-Fos, and c-Jun, were
consistently increased (SI Appendix, Fig. S1F). Strikingly,
among the oncogenes detected, only the MYC protein rapidly
vanished during the necroptotic process (SI Appendix, Fig.
S1F). Accordingly, mRNA levels of several MYC target genes
are indeed altered during necroptosis, suggesting that MYC
might be associated with the necroptosis signaling pathway (SI
Appendix, Fig. S1G).
RIPK3 Activation Leads to the Proteasomal Degradation of MYC
during Necroptosis. We next evaluated whether MYC expression
was also affected by canonical TNF-α signaling. However, the
MYC levels were slightly increased in cells stimulated with TNF-α
alone or TNF-α plus BV6 (TB), which led to NF-κB activation, as
evidenced by cIAP2 induction, or apoptosis, as evidenced by
poly(ADP-ribose) polymerase (PARP) cleavage (SI Appendix, Fig.
S2A). The inhibition of caspase activity with zVAD-fmk, which leads
to RIPK3 phosphorylation, down-regulated MYC, suggesting that
MYC suppression might occur downstream of complex IIb forma-
tion and might require RIPK3 activation (SI Appendix, Fig. S2 A and
B) (34). Furthermore, treatment of the FADD-deficient (FADD-
def.) Jurkat cells with TNF-α alone or TNF-α plus birinapant, which
is known to induce necroptosis (35), reduced the levels of the MYC
protein (SI Appendix, Fig. S2C) (35). Consistently, the treatment of
HeLa cells stably expressing RIPK3 with TNF-α, BV6, and zVAD-
fmk decreased MYC expression, which was not observed in HeLa
cells lacking RIPK3 expression, indicating that RIPK3 is required
for MYC down-regulation (SI Appendix, Fig. S2D). Similarly, MYC
up-regulation induced by TNF-α alone and down-regulation by
necroptotic stimulation were also observed in L929 murine fibro-
blasts and TC-1 murine lung cancer cells, indicating a con-
served mechanism underlying necroptosis-mediated MYC
down-regulation (SI Appendix, Fig. S2 E and F). Since nec-
roptotic cells release DAMP molecules that influence neigh-
boring cells (33), we tested whether MYC down-regulation is
mediated by paracrine signaling. However, the conditioned
medium from necroptotic cells did not affect MYC expression,
suggesting that necroptosis induces MYC down-regulation in a
cell-autonomous manner (SI Appendix, Fig. S2G)
To identify the plausible pathways involved in MYC down-
regulation, we employed several inhibitors of necroptosis sig-
naling proteins, such as RIPK1, RIPK3, and MLKL. Notably,
down-regulation of MYC during necroptosis was prevented by
two RIPK1 inhibitors (necrostatin-1 [Nec-1] and GSK′963) and a
RIPK3 inhibitor (GSK′872), but not by the MLKL inhibitor
(necrosulfonamide [NSA]) (SI Appendix, Fig. S2 H and I). In
addition, RIPK3 depletion prevented MYC down-regulation,
whereas the levels of the MYC protein were decreased in
MLKL-depleted cells (SI Appendix, Fig. S2 J and K). Based on
these data, RIPK3 activation induces MYC down-regulation
during necroptosis in an MLKL-independent manner.
We next investigated how MYC is down-regulated upon nec-
roptosis. When levels of the MYC mRNA were assessed using
qRT-PCR, levels of the MYC mRNA decreased at 1 h post-TBZ
stimulation but recovered after 3 to 5 h (SI Appendix, Fig. S2L).
An early decrease in the mRNA levels of MYC was also ob-
served when cells were treated with TNF-α alone or TB, sug-
gesting that the down-regulation of the MYC mRNA after 1 h of
stimulation was not specific to necroptosis (SI Appendix, Fig.
S2L). In addition, the MYC mRNA levels rebounded upon
necroptosis, whereas the levels of the MYC protein were still
decreased, suggesting that the levels of the MYC protein are
regulated posttranslationally (SI Appendix, Fig. S2 A and M).
To address whether MYC is degraded by the proteasome upon
necroptosis, we stimulated HT-29 cells with TBZ in the presence
of MG132, a proteasome inhibitor. However, proteasome inhi-
bition completely abrogated the activation of the RIPK3 path-
way, as previously reported (36), in part by suppressing the
cIAP1 degradation induced by BV6, resulting in sustained MYC
expression (SI Appendix, Fig. S2N). Thus, MG132 was added
after a 2-h stimulation of HT-29 cells with TBZ, enabling early
RIPK3 activation, and MYC destabilization was prevented by
MG132 (SI Appendix, Fig. S2O). The observation that ectopically
introduced MYC was also degraded during necroptosis excludes
the possibility of transcriptional control of MYC by necroptosis
(SI Appendix, Fig. S2P). Finally, we observed an increase in the
polyubiquitination of endogenous MYC during necroptosis (SI
Appendix, Fig. S2Q). Collectively, these data indicate that nec-
roptosis induces the polyubiquitination and proteasomal degra-
dation of MYC.
MYC Functions as an Antinecroptotic Factor in TNF-α–Induced Necroptosis.
Although MYC is known to play key roles in cell proliferation and
apoptosis (37, 38), its role in necroptosis is unknown. The decreased
levels of MYC upon necroptotic stimulation prompted us to search
for a possible role for MYC in necroptosis. When MYC was ablated
using small-interfering RNA (siRNA) pools containing four different
siRNAs against MYC, HT-29 cells became exceptionally susceptible
to TBZ-induced cell death and showed increased levels of phospho-
RIPK3 and phospho-MLKL (Fig. 1 A–C). However, HT-29 cells
stably expressing MYC became resistant to necroptosis and showed
delays in the phosphorylation of RIPK3 and MLKL (Fig. 1 D–F).
Notably, in cells with varying degrees of MYC overexpression, the cell
death process was increasingly inhibited in proportion to the in-
creasing concentration of MYC, indicating the compelling anti-
necroptotic effects of MYC at different concentrations (Fig. 1 G and
H). Reconstitution of siRNA-resistant MYC (MYCRes#1) in MYC-
depleted cells reversed the sensitivity to necroptosis and the RIPK3
and MLKL phosphorylation, suggesting that MYC is a negative
regulator of necroptosis (Fig. 1 I and J).
We generated two MYC knockout (KO) cell lines, KO#1 and
#2 using the CRISPR/Cas9 method and confirmed MYC KO by
sequencing and immunoblot analyses to further validate the
negative effect of MYC on necroptosis and eliminate any off-
target effects (SI Appendix, Fig. S3 A–C). Consistent with the
results of the knockdown experiments, both of the MYC KO
cell lines were more sensitive to TBZ-induced necroptosis than
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TB-induced apoptosis (SI Appendix, Fig. S3 D and E). Recon-
stitution of MYC expression (MYCRes) in the MYC KO#1 cell
line again reversed the sensitivity to necroptosis (Fig. 1 K and L).
We next asked whether MYC depletion might affect other nec-
roptotic signaling pathways. TNF-α–induced necroptosis sensitized
by CHX or 5z7 (TAK1 inhibitor) was further increased by MYC
depletion in HT-29 cells (SI Appendix, Fig. S4A). In addition, nec-
roptosis induced by TNF-α alone (T), TNF-α/birinapant (T/Bir), or
TNFα/5z7 (T/5z) in FADD-def. Jurkat cells was also enhanced fol-
lowingMYC depletion (SI Appendix, Fig. S4B). Furthermore, MYC-
depleted cells were more sensitive to necroptosis induced by other
stimuli—such as TRAIL, LPS, and IFN-γ—all of which depend on
RIPK3 (SI Appendix, Fig. S4 C–E). Consistent with the results
obtained from human cells, mouse L929 and TC-1 cells showed
increased sensitivity to TZ- or TBZ-induced necroptosis upon MYC
depletion (SI Appendix, Fig. S4 F–I). These data suggest a conserved
role for MYC in regulating TNF-α–induced necroptosis.
We next examined whether MYC also affects the RIPK1-
dependent apoptosis induced by TNF-α plus Smac mimetics.
MYC ablation failed to promote TNF-α–mediated apoptosis, but
it facilitated the necroptosis of HT-29 and HeLa-RIPK3 cells
(Fig. 2 A–D). The increase in necroptosis induced by MYC de-
pletion was prevented by Nec-1, indicating the association of
MYC with necroptosis (Fig. 2 A–D). MYC depletion increased
the levels of the phosphorylated forms of RIPK3 and MLKL, as
well as MLKL oligomerization (Fig. 2 C and E), suggesting that
MYC might be involved in the pivotal regulatory axis of the
RIPKs and MLKL.
MYC Suppresses TNF-α–Induced Necroptosis by Suppressing Necrosome
Formation. Since the formation of complex IIb and the necrosome
are essential for apoptosis and necroptosis, we examined the effect
of MYC on the formation of these complexes upon stimulation
(34). The TBZ-induced recruitment of necrosome components,
such as RIPK3, RIPK1, MLKL, and FADD to caspase-8 was in-
creased in the MYC-depleted and MYC-KO cells compared to
the control cells (Fig. 3 A and B). However, remarkable increases
in TB-induced complex IIb formation were not observed in HT-29
Fig. 1. MYC suppresses TBZ-induced necroptosis. (A–C) MYC depletion facilitates necroptosis. HT-29 cells transfected with a nontargeting siRNA pool (siNT)
or MYC siRNA pool (siMYC) were treated with TBZ as indicated and subjected to a photomicrograph analysis (A), cell viability analysis (B), and immunoblotting
analysis (C). Data are the means ± SD, n = 3, with **P < 0.01 and ***P < 0.001 compared to siNT with a two-sided Student’s t test. (Scale bars, 100 μm.) The
asterisk in C indicates MLKL or p-MLKL. (D–F) MYC overexpression delays necroptosis. HT-29 cells stably expressing Mock or MYC were treated with TBZ for
the indicated times and analyzed as described in A–C. Data are the means ± SD, n = 3, with ***P < 0.001 and n.s. = nonsignificant compared to the mock
control with two-sided Student’s t test. (Scale bars, 100 μm.) (G and H) MYC suppresses necroptosis in a dose-dependent manner. HT-29 cells were transduced
with increasing amounts of lentiviral MYC or the mock control. Stable HT-29 cell lines were transfected with siNT or siMYC as indicated and treated with TBZ
for 18 h for assessments of cell viability (G) or for 2 to 4 h for the immunoblot analysis (H). (I and J) MYC reconstitution rescues MYC-depleted HT-29 cells from
accelerated necroptosis. HT-29 cells stably expressing siRNA-resistant MYC (MYCRes#1) were transfected with individual MYC siRNA (siMYC#1) and treated with
TBZ for 6 h (I) or the indicated times (J). After TBZ stimulation, HT-29 cells were analyzed as described in (B and C). The asterisk indicates RIPK3. (K and L)
CRISPR/Cas9-mediated KO of MYC enhances necroptosis, which is rescued by MYCRes overexpression. MYC KO#1 HT-29 cells lentivirally transduced with Mock
or MYCRes were treated with TBZ for 10 h (K) or the indicated times (L). Data are the means ± SD, n = 3, with **P < 0.01 according to a two-sided Student’s
t test.
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cells or HeLa cells upon MYC depletion, both of which lack
RIPK3 activation (Fig. 3 A and C). To further validate necrosome
formation, we carried out gel-filtration analysis. Similar to previ-
ous observations, upon TBZ stimulation, the RIPK1, RIPK3, and
MLKL proteins were detected in a greater than 2-MDa fraction,
which might be the necrosome (Fig. 3D) (29, 39, 40). Although
most of these proteins were still present in their monomeric forms
in control cells treated with TBZ, large portions of RIPK3,
RIPK1, and MLKL shifted to earlier 2-MDa fractions in the
MYC-depleted cells treated with TBZ, suggesting that MYC
constrains necrosome formation (Fig. 3D). Although MYC neg-
atively regulates necrosome formation, this molecule was not de-
tected in complex IIb or in the necrosome (Fig. 3A). Furthermore,
little change was observed in the fraction containing the MYC
proteins in the gel-filtration analyses upon necroptotic stimulation,
suggesting that MYC might not be an integral part of the
necrosome complexes (Fig. 3D).
Cytoplasmic MYC Functionally Suppresses RIPK3-Dependent Necroptosis.
Because MYC is a transcription factor (41), we aimed to determine
whether MYC transcriptional activity is involved in the suppression
of necroptosis. When MAX, a cofactor of MYC (42), was depleted
in HT-29 cells, cell viability and the levels of necroptotic markers,
such as p-MLKL and p-RIPK3, were relatively unchanged, sug-
gesting that MAX might not be involved in this process (Fig. 4 A–
D). Since MYC is also localized to the cytoplasm (Fig. 4E) (43–45)
and appears to regulate the necrosome complex, we asked whether
cytoplasmic MYC might suppress necroptosis. We constructed a
series of MYC mutants with point mutations in nuclear localization
signals (NLSs) 1 and 2 to address these questions; these point
mutants show weak localization or lack the ability to localize to the
nucleus based on previous reports (41). Among the various MYC
mutants, the NLS1/2 mutant—with lysine residues at 323, 326, and
371 and arginine residues at 364, 366, and 367 replaced with alanine
residues—was almost completely excluded from the nucleus and
was defective in inducing its target-gene expression (SI Appendix,
Fig. S5 A–D). This mutant still suppressed necroptosis as well as
MYC WT, indicating that cytoplasmic MYC might suppress TNF-
α–induced necroptosis (SI Appendix, Fig. S5E). Furthermore, the
Fig. 2. MYC restrains necroptosis but not apoptosis. (A and B) MYC knockdown facilitates necroptosis but not apoptosis. HT-29 cells transfected with siNT or
siMYC were treated with T/Bi, T/Bi/Z, or T/Bi/Z plus Nec-1 (T/Bi/Z/N) for 6 h. After 6 h, the cells were stained with Annexin V and 7-AAD for flow cytometry
analysis. A representative plot is shown in A, and three independent analyses are shown in B. Data are the mean s± SD, n = 3, with **P < 0.01 and n.s. =
nonsignificant compared to siNT with a two-sided Student’s t test. (C) HT-29 cells transfected with siNT or siMYC were treated with TBi or TBiZ. Activation of
the necroptosis or apoptosis pathways was analyzed by evaluating the phosphorylation of RIPK3 and MLKL and cleavage of caspase-8 and PARP using im-
munoblotting. (D) MYC depletion accelerates TBZ-induced necroptosis, but not TB-induced apoptosis, in HeLa-RIPK3 cells. The HeLa stable cell line consti-
tutively expressing mock (HeLa-pBabe) or RIPK3 (HeLa-RIPK3) was treated with TB for 6 h or TBZ for 4 h and examined for cell viability. Data are the means ±
SD, n = 3, with *P < 0.05, **P < 0.01, ***P < 0.001 and n.s. = nonsignificant compared to siNT with a two-sided Student’s t test. (E) The HeLa cells constitutively
expressing the mock (HeLa-pBabe) or RIPK3 plasmid (HeLa-RIPK3) were treated with TB for 3 h or TBZ for 2 h and lysed in nonreducing buffer or reducing
buffer containing β-mercaptoethanol, followed by immunoblot analyses.
Seong et al. PNAS | August 18, 2020 | vol. 117 | no. 33 | 19985
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NLS1/2 mutant restored the increased necroptotic cell death after
the MYC deletion (Fig. 4 F and G).
We employed a cleaved fragment of endogenous MYC named
MYC-nick that does not contain the NLSs and is known to lo-
calize exclusively in the cytoplasm with no MYC transcriptional
activities to further determine if the cytosolic function of MYC is
physiologically associated with the suppression of necroptosis
(46, 47). We also detected two cytoplasmic isoforms of MYC
with molecular masses of ∼40 kDa and 50 kDa in HT-29 cells
cultured at high density, as previously reported (Fig. 5A) (46, 47).
Although MYC-nick is reported to be a 42-kDa protein (46, 47),
FLAG-MYC-nick (1–298) is detected at ∼55 kDa (Fig. 5B).
Furthermore, this band was not detected in cells expressing the
Δ290–300 mutant of MYC, which is resistant to protease
cleavage and does not produce MYC-nick (Fig. 5C) (46, 47).
Therefore, we concluded that the band detected at ∼50 kDa is an
endogenous MYC-nick (1–298) isoform in HT-29 cells under our
conditions, and size difference of MYC-nick compared to other
reports might be derived from difference in Western blotting
protocol and molecular weight markers. The levels of MYC-nick
were also decreased relative to MYC WT in cells exposed to
necroptotic stimuli (Fig. 5D). The reduction in MYC-nick levels
might be due to the reduced levels of MYC and the degradation
of MYC-nick itself during necroptosis, since the levels of ectopic
MYC-nick were also decreased following necroptosis (SI Ap-
pendix, Fig. S6A). Notably, MYC-nick suppressed MLKL phos-
phorylation and necroptotic cell death (Fig. 5E and SI Appendix,
Fig. S6).
Since the cytoplasmic NLS1/2 mutant and MYC-nick could
inhibit necroptosis, we hypothesized that MYC would interact
with RIPK3 in the cytoplasm. First, MYC was observed to di-
rectly interact with RIPK3 in vivo and in vitro (SI Appendix, Fig.
S7 A and B). Physiologically, endogenous MYC was associated
with endogenous RIPK3, and this association was abolished
upon necroptosis (SI Appendix, Fig. S7 C and D). The dissocia-
tion of MYC from RIPK3 was abrogated by GSK′963, but not by
GSK′872, suggesting that RIPK1 kinase activity, but not RIPK3
kinase activity, is responsible for the dissociation (SI Appendix,
Fig. S7D). In particular, MYC and RIPK3 were colocalized and
interacted in the cytoplasm (Fig. 5 F and G and SI Appendix, Fig.
S7E). Furthermore, both full-length MYC and MYC-nick also
interacted with RIPK3 in the cytoplasm, supporting our obser-
vation that both MYC and MYC-nick would participate in
suppressing necroptosis in the cytoplasm (Fig. 5 H and I). No-
tably, endogenous MYC-nick, similar to MYC, interacted with
RIPK3 in HT-29 cells (Fig. 5J). Indeed, the Δ290–300 mutant
defective in MYC-nick production still prevented necroptosis
(Fig. 5 C and K). Based on these data, both cytoplasmic MYC
WT and MYC-nick might be responsible for preventing nec-
roptosis in HT-29 cells. In addition to RIPK3, RIPK1 also
interacted with MYC (SI Appendix, Fig. S7 F and G). However,
we failed to detect the endogenous interaction between MYC
and RIPK1, possibly suggesting a very transient or weak inter-
action between the two proteins (SI Appendix, Fig. S7 H and I).
MYC Prevents the Formation of RIPK1–RIPK3 Complexes, Suppressing
Necroptosis. Since MYC directly binds to RIPK3 and inhibits
RIPK3 activation, we hypothesized that MYC might directly
hinder the complex formation between RIPK3 and RIPK1. In-
terestingly, the interaction between RIPK1 and RIPK3 was re-
duced upon MYC overexpression, indicating that necrosome
formation was decreased in HT-29 cells stably expressing MYC
(Fig. 6A). Furthermore, the increased necrosome formation
observed in MYC KO cells during necroptosis was suppressed by
the reconstitution with MYC WT or the NLS1/2 mutant (SI
Appendix, Fig. S5F). Notably, recombinant GST-MYC purified
Fig. 3. MYC negatively regulates the formation of the RIPK3-containing necrosome. (A) MYC depletion promotes necrosome formation upon TBZ stimu-
lation. HT-29 cells transfected with siNT or siMYC were treated with TB or TBZ. After treatment, the cell lysates were immunoprecipitated with an anticaspase-
8 antibody and analyzed using immunoblotting. The asterisk indicates RIPK3. (B) MYC deletion facilitates necrosome formation. MYC WT and KO HT-29 cells
were treated with TBZ for the indicated times, followed by immunoprecipitation with an RIPK3 antibody. (C) MYC depletion does not regulate TBZ-induced
RIPK1-dependent complex IIb formation in HeLa cells. HeLa cells were transfected with siMYC and treated with TBZ for 3 h. The complex IIb was isolated by
immunoprecipitation of caspase-8. (D) HT-29 cells were transfected with the indicated siRNA and treated with TBZ for 3 h. The cell lysates were fractionated
according to molecular size by gel-filtration chromatography and examined using immunoblotting.
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from wheat germ cells inhibited the interaction between the
RHIM domains of RIPK1 and RIPK3 in vitro (Fig. 6B).
We conducted a domain-mapping analysis to identify the do-
mains of MYC essential for suppressing necroptosis and
revealed that the N and C termini of RIPK3 and MYC were
involved in their interactions, suggesting the presence of multiple
binding sites between the two proteins (SI Appendix, Fig. S8 A–
D). Furthermore, the N terminus of MYC (1–144) preferentially
interacted with the C terminus of RIPK3 (294–518), while the C
terminus of MYC (368–439) bound to the N-terminal kinase
domain of RIPK3 (1–293) (SI Appendix, Fig. S8E). In particular,
the N terminus of MYC failed to interact with RIPK3 lacking the
RHIM domain (294–454), implying a pivotal role for the RHIM
domain in this interaction (SI Appendix, Fig. S8F). Supporting
this hypothesis, the mutation of VQVG, critical residues in the
RIPK3 RHIM domain, to AAAA abrogated the interaction of
RIPK3 with MYC (SI Appendix, Fig. S8 G and H). Similarly,
MYC also interacted with the RHIM domain of RIPK1 (SI
Appendix, Fig. S8 I–K). We tested whether MYC fragments
suppressed necroptosis by binding to RIPK3 and RIPK1, and
found that both the N and C termini of MYC inhibited TBZ-
induced necroptosis (SI Appendix, Fig. S8 L and M). Although
the C terminus of MYC bound to the kinase domain of RIPK3
and suppresses necroptosis, MYC did not inhibit the autokinase
activity of RIPK3 (SI Appendix, Fig. S8N). However, the N ter-
minus of MYC (1–144) directly disrupted the formation of the
RIPK1–RIPK3 complex in vitro (Fig. 6C). Thus, MYC abrogates
binding of the RIPK3 RHIM domain to RIPK1, possibly sup-
pressing multimerization and amyloid formation of the necrosome
(48, 49).
MYC Depletion Induces the Formation of Sublethal RIPK1–RIPK3
Complexes in a Kinase-Dependent Manner in the Absence of
Necroptotic Stimuli. Notably, we consistently observed increased
levels of the RIPK3 and RIPK1 proteins in the MYC-depleted
and KO cells (Fig. 6 D and E and SI Appendix, Fig. S3C).
However, the levels of the RIPK1 and RIPK3 mRNAs and levels
of the caspase-8, MLKL, cIAP-1/2, and c-FLIP proteins were not
affected by changes in the levels of the MYC protein in our
system (SI Appendix, Figs. S3C and S9 A and B) (50). In contrast,
MYC overexpression reduced the levels of the RIPK1 and
RIPK3 proteins without significant changes in the mRNA levels
(Fig. 1F and SI Appendix, Fig. S9 C–E). In addition, the MYC
NLS1/2 mutant, which lacks of transcriptional activity, reduces
the levels of the RIPK1 and RIPK3 proteins (Fig. 4G), implying
that MYC controls the steady-state levels of RIPK1 and RIPK3
in the cytoplasm. As shown in our previous study, RIPK1 and
RIPK3 are simultaneously degraded via the CHIP–lysosome-
dependent pathway, which suppresses necroptosis (51). Based on
these observations, we tested whether MYC-mediated RIPK1
and RIPK3 protein destabilization is also dependent on these
systems. Knockdown of MYC, CHIP, or both proteins exerted
similar effects on the levels of the RIPK1 and RIPK3 proteins,
suggesting that MYC and CHIP may function in the same axis
Fig. 4. MYC controls necroptosis in a transcription-independent manner. (A and B) Immunoblot (A) and qRT-PCR (B) analyses showing the knockdown
efficiency in HT-29 cells. (C and D) MAX depletion fails to facilitate TNF-α–mediated necroptosis. HT-29 cells transfected with the indicated siRNA pools were
treated with TBZ as indicated, followed by cell viability (C) and immunoblot (D) analyses. Data are the means ± SD, n = 3, with ***P < 0.001, and n.s. =
nonsignificant compared to siNT at each point with a two-sided Student’s t test. The asterisk indicates MLKL. (E) Immunofluorescence staining showing the
subcellular localization of endogenous MYC and RIPK3 using anti-MYC (#5605, Cell Signaling) and anti-RIPK3 antibodies (#13526, Cell Signaling) in HT-29 cells.
(Scale bars, 20 μm.) (F and G) Both MYC WT and the NLS1/2 mutant (NLS1/2m) suppress the increased necroptosis observed in HT-29/MYC KO cells. HT-29/MYC
KO cells reconstituted with lentiviral MYC WT or NLS1/2m cells were treated with TBZ in the absence or presence of GSK′963 (F) or with TBZ for the indicated
times (G). Cell viability (F) and immunoblot analyses (G) were performed to monitor necroptosis.
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(SI Appendix, Fig. S9F). The destabilization of RIPK1 and
RIPK3 by MYC overexpression was blocked by treatment with
the lysosome inhibitors E64d and pepstatin A (pepA), but not
the proteasome inhibitor MG132 (SI Appendix, Fig. S9G). Fur-
thermore, MYC-mediated RIPK1 and RIPK3 degradation was
completely inhibited by CHIP ablation (SI Appendix, Fig. S9H).
Fig. 5. Both full-length MYC and MYC-nick are responsible for suppressing necroptosis. (A) The levels of MYC and MYC-nick in the cytoplasm and nucleus
were determined by performing an immunoblot analysis using anti-MYC antibodies (#5605, Cell Signaling). The asterisks indicate a MYC variant. (B and C)
Expression of FLAG-tagged MYC, MYC-nick, and MYC Δ290–300 in HT-29/MYC KO cells. HT-29/MYC KO cells were reconstituted with lentiviral MYC expression
vectors, followed by immunoblot analyses. (D) Levels of both the MYC and MYC-nick proteins were decreased in response to TBZ stimulation in HT-29 cells. (E)
Analysis of the viability of HT-29 cells/MYC KO cells reconstituted with MYC and MYC-nick after treatment with TBZ in the absence or presence of GSK′963. Data
are the means ± SD, n = 3, with **P < 0.01 and ***P < 0.001 compared to MYC KO/Mock cells with a two-sided Student’s t test. (F) Immunofluorescence staining
showing cytoplasmic colocalization of HA-MYC and RIPK3-GFP transiently expressed in HeLa cells. (Scale bars, 20 μm.) (G) Interaction between endogenous RIPK3
and FLAG-MYC in the cytoplasm. Cytoplasmic and nuclear extracts from HT-29 cells stably expressing FLAG-MYC were immunoprecipitated with anti-FLAG an-
tibodies. FLAG-MYC-bound proteins were isolated using a FLAG peptide to eliminate nonspecific interactions, followed by immunoblotting. (H and I) Immu-
noprecipitation analysis using cytoplasmic extracts of 293FT cells transfected with RIPK3 and MYC or MYC-nick (1–298), as indicated. Immunoprecipitates were
eluted with the HA or FLAG peptide. (J) Endogenous MYC and MYC-nick physiologically associated with endogenous RIPK3 in the cytoplasm. Cytoplasmic and
nuclear extracts from HT-29 cells treated with TBZ as indicated were immunoprecipitated using an anti-RIPK3 antibody to examine the endogenous interaction
between RIPK3 and MYC. (K) Analysis of the viability of the indicated cells after treatment with TBZ. Data are the means ± SD, n = 3, with **P < 0.01 and ***P <
0.001 compared to MYC KO/Mock cells with a two-sided Student’s t test.
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These observations indicated that the MYC-dependent destabi-
lization of RIPK proteins requires the presence of the CHIP–
lysosome-dependent pathway.
Because MYC inhibits the interaction between RIPK1 and
RIPK3 and MYC ablation increases the RIPK1 and RIPK3
protein levels, we hypothesized that MYC silencing would lead
Fig. 6. MYC interacts with RIPK3 and disrupts the interaction between RIPK1 and RIPK3. (A) MYC prevents RIPK3 from interacting with RIPK1. HT-29 cells
stably expressing FLAG-MYC or empty vector were immunoprecipitated with an anti-RIPK3 antibody. (B) MYC prevents the interaction between RIPK1 and
RIPK3 in vitro. Recombinant GST-MYC purified using a wheat germ system was added to the recombinant MBP-RIPK1 RHIM domain (496–583) and His-MBP-
RIPK3 (388–514) as indicated, followed by Ni2+-pulldown analysis. RIPK3-bound RIPK1 was detected using anti-RIPK1 antibodies. (C) The N terminus of MYC is
responsible for suppressing the RIPK1 and RIPK3 interaction. Bacterially purified MBP-MYC (1–144) was added to the RHIM domains of RIPK1 and RIPK3. The
interaction of RIPK1 and RIPK3 was determined as described above. (D and E) MYC ablation increases the levels of the RIPK1 and RIPK3 proteins. The levels of
the RIPK1, RIPK3, and pMLKL proteins in HT-29 (D) and HeLa/RIPK3 cells (E) were analyzed using immunoblotting after MYC knockdown and/or treatment
with 30 μM Nec-1 or 3 μM GSK′872. (F and G) RIPK1 and RIPK3 form a complex in MYC-depleted HT-29 cells. HT-29 cells transfected with the indicated siRNAs
were treated with DMSO, GSK′963, or Nec-1. After chemical treatment, an immunoprecipitation assay was carried out using an anti-RIPK3 antibody. (H) MYC
depletion induces the formation of small and inactive necrosome complexes. HT-29 cells were transfected or treated with the indicated siRNA or stimuli,
respectively. The cell lysates were fractionated according to molecular size by gel-filtration chromatography and examined by immunoblotting. (I) MYC
induces the accumulation of RIPK1 and RIPK3 proteins in the soluble fraction. HT-29 cells were transfected with MYC siRNA and treated with TBZ for 4 h.
Cells were then fractioned into lysis buffer soluble (Sol.) and insoluble (Insol.) fractions, followed by immunoblot analysis. The phosphorylated form of
RIPK3 (p-RIPK3) is indicated by the arrowhead, and the asterisks indicate p-MLKL.
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to sublethal RIPK1–RIPK3 complex formation, which in turn
allows these proteins to stabilize themselves but no other related
proteins. Indeed, while RIPK3 might rarely interact with RIPK1
under normal conditions, the association between endogenous
RIPK1 and RIPK3 was detected in MYC-depleted cells without
necroptotic stimulation (Fig. 6 F and G). Moreover, the associa-
tion between RIPK3 and MLKL was strengthened by MYC de-
pletion (Fig. 6G). These enhanced associations were weakened by
GSK′963 or Nec-1, suggesting a requirement for RIPK1 kinase
activity (Fig. 6 F and G). Furthermore, when the MYC-depleted
cells were treated with Nec-1 or GSK′872, the accumulation of
RIPK3 and phosphorylation of MLKL were suppressed, suggest-
ing the necessity of the kinase activities of RIPK1 and RIPK3 for
the stabilization of these proteins (Fig. 6 D and E). Stabilization of
RIPK1 and RIPK3 upon MYC depletion or deletion led to the
phosphorylation of RIPK1, RIPK3, and MLKL in the absence of
necroptotic stimuli, but the levels of these phosphorylated proteins
were much lower than the levels observed during necroptosis (SI
Appendix, Fig. S9 I and K). Notably, the phospho-RIPK3 S227
antibody appears to be very specific, as this antibody did not detect
the RIPK3 S227A mutant (SI Appendix, Fig. S9J). As a result,
MYC depletion or deletion did not induce MLKL oligomerization
and cell death in the absence of necroptotic stimuli (Fig. 2E and SI
Appendix, Fig. S9K). Interestingly, the RIPK3 and MLKL phos-
phorylation observed upon MYC depletion were independent of
TNF-α autocrine signaling (SI Appendix, Fig. S9 L and M), sug-
gesting a direct role for MYC in the regulation of necroptosis
mediators.
We performed gel-filtration chromatography to further as-
certain whether MYC obstructs the formation of the RIPK1–
RIPK3 complex in unstimulated cells and found that RIPK1 and
RIPK3 were present in the higher molecular mass fractions at
∼300 kDa to 1 MDa in MYC-depleted cells compared to control
cells, whereas the distributions of the other proteins, such as
caspase-8, MLKL, and TRAF2, remained the same (Fig. 6H and
SI Appendix, Fig. S9N). However, RIPK1 and RIPK3 in MYC-
depleted cells appeared to form smaller complexes than the
typical necrosome, which is larger than 2 MDa (Fig. 6H) (29, 39,
40). Notably, RIPK1 and RIPK3 were mainly present in the
soluble fraction of MYC-depleted HT-29 cells, but they rapidly
shifted to the insoluble fraction in response to necroptotic
stimulation (Fig. 6I). Our findings revealed that MYC depletion
induces the preassembly of small and soluble necrosomes, which
are insufficient to trigger necroptosis but may accelerate nec-
roptotic kinesis by facilitating the rapid formation of large and
insoluble necrosomes upon necroptotic stimulation.
Suppression of MYC in Leukemia Cells Facilitates Necroptosis-
Dependent Cell Death In Vivo and In Vitro. The observation that
MYC functions as an antinecroptotic factor suggests the possible
therapeutic potential of targeting necroptosis in cancer treat-
ment. We focused on human leukemia cells because frequent
overexpression and activation of MYC in human leukemia form
the basis of anti-MYC therapy (52, 53). In addition, at very low
concentrations, a Smac mimetic resulted in substantially in-
creased sensitivity of several types of leukemia cells to apoptosis
and necroptosis through autocrine TNF-α production (Fig. 7A)
(54–57). We therefore examined the expression of MYC and cell
death-related proteins to test the sensitivity to necroptosis of
these cells (Fig. 7B). Similar to previous observations, cell lines
expressing RIPK3, such as Molm13, Molm14, and MV4;11, were
sensitive to necroptosis induced by birinapant and zVAD-fmk,
but not apoptosis induced by birinapant alone (Fig. 7C) (58, 59).
HL-60 and CCRF-CEM cells appeared to be sensitive to both
apoptosis and necroptosis, whereas NB4 cells lacking RIPK3
were sensitive to apoptosis (Fig. 7C). In addition, RS4;11, U937,
and KG-1α cells were only resistant to Smac mimetic-induced
cell death (Fig. 7C). We therefore chose Molm13 cells for
further analysis because of their high sensitivity to necroptosis in
the absence of TNF-α through autocrine TNF-α production (SI
Appendix, Fig. S10A) (54–57). MYC-depleted Molm13 cells were
also more susceptible to necroptosis induced by birinapant and
zVAD-fmk (SI Appendix, Fig. S10B). We also tested another
caspase inhibitor, emricasan, which has been examined in clinical
trials (54). Again, MYC depletion sensitized cells to necroptosis
induced by birinapant and emricasan. Similar to HT-29 cells,
MYC depletion leads to an increase in the formation of the
necrosome complex and phosphorylation of RIPK3 and MLKL
upon necroptotic simulation in Molm13 cells (Fig. 7 D–F and SI
Appendix, Fig. S10 C and D). These results imply that MYC also
plays a key role in protecting leukemia cells from necroptosis.
We next conducted a xenograft analysis using MYC-depleted
Molm13 cells. Mice with subcutaneous tumors were treated with
birinapant and emricasan every 2 d (Fig. 7G). Tumors treated
with birinapant plus emricasan were slightly smaller than those
treated with the vehicle control, consistent with a previous report
(Fig. 7 G–J) (54). Although MYC depletion did not exert a
significant effect on tumor growth, it substantially inhibited tu-
mor growth in mice injected with birinapant and emricasan (Fig.
7 G–J). Strikingly, the tumor mass of MYC-depleted Molm13
cells subjected to the same treatment was significantly reduced,
while the tumor mass of cells that did not receive treatment was
not. Therefore, although MYC knockdown did not substantially
affect tumor growth, it noticeably sensitized the tumor to nec-
roptotic shock (Fig. 7 G–J). Collectively, the down-regulation of
MYC renders leukemia cells more sensitive to necroptosis both
in vivo and in vitro, and thus the concept of necroptosis-induced
cell death can be applied to cancer therapy.
Discussion
MYC is a versatile and potent oncogene that functions as a
master regulator of cancer cells by regulating multiple processes,
such as apoptosis, proliferation, stemness, metabolism, and im-
munity (53, 60–62). While most of these functions are inherently
associated with MYC transcriptional activities, here we report an
unconventional cytosolic role for MYC as a direct negative
regulator of necroptosis wherein MYC functions by interacting
with RIPK3, which is a pivotal factor in necroptosis. When the
MYC levels were low or ablated, stable RIPK1–RIPK3 com-
plexes with an insufficient capability to induce necroptotic cell
death spontaneously formed. Stabilization of RIPK1–RIPK3
complexes relies on phosphorylation because the inhibition of
RIPK1 or RIPK3 abolished complex formation and destabilized
the RIPK1 and RIPK3 proteins (Fig. 6 D–G). Upon necroptotic
stimulation, these small complexes act as seeding complexes,
leading to the rapidly increased formation of active necrosomes,
inducing massive necroptotic cell death (63). When MYC is
present, MYC directly interacts with RIPK3, thereby preventing
the spontaneous formation of the RIPK1 and RIPK3 complexes.
This interaction might render CHIP E3 ubiquitin ligase acces-
sible to RIPK1 and RIPK3, leading to their lysosomal degrada-
tion, as reported in a previous study (51). Upon necroptotic
stimulation, the MYC interaction with RIPK3 delayed the for-
mation of necrosomes, resulting in the suppression of otherwise
rapidly occurring necroptosis.
The inhibitory effect of MYC on necroptosis appears to occur
in the cytosol because the MYC mutants MYC-nick and NLS1/
2m, which are incapable of localizing to the nucleus, suppressed
necroptosis (Figs. 4 and 5 and SI Appendix, Figs. S5 and S6).
Nevertheless, we were unable to exclude a possible nuclear in-
teraction between RIPK3 and MYC, based on a recent report
suggesting that the RIPK3 and RIPK1 association in the nucleus
might facilitate prenecrosome complex formation, which can
accelerate necroptosis (63, 64). After treatment with leptomycin
B (LMB), an inhibitor of nuclear export, we observed the ac-
cumulation and colocalization of RIPK3 and MYC in the
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nucleus in the absence of necroptotic stimuli (SI Appendix, Fig.
S11 A and B). While RIPK3 forms large aggregates in the cy-
toplasm in response to the induction of necroptosis with TBZ, it
exhibited nuclear localization and a cytoplasmic small punctate
structure upon treatment with TBZ plus LMB (SI Appendix, Fig.
S11C). These data indicate that the interaction between the
nuclear shuttling of RIPK3 and MYC also occurs in the nucleus
and might suppress necroptosis.
Fig. 7. Down-regulation of MYC sensitizes acute myeloid leukemia cells to necroptosis induced by birinapant plus the caspase inhibitor and increases the
antileukemia activity in xenograft models. (A) The effects of birinapant (Bi) on the levels of cIAP1 in Molm13 cells. (B) Immunoblot analysis of various leukemia
cell lines. (C) Each leukemia cell line was treated with the indicated concentrations of birinapant alone or birinapant plus 20 μM zVAD for 24 h, followed by a
FACS analysis to measure cell viability. (D–F) Necroptosis and necrosome analysis of Molm13 cells stably expressing shMYC and treated with 25 nM birinapant
plus 1 μM emricasan. GSK′963 (RIPK1 inhibitor) was administered to cells at 100 nM to inhibit RIPK1-dependent necroptosis. After treatment, the cells were
examined using a FACS analysis to determine the percentage of cell death (D), using an immunoblot analysis to determine the phosphorylation of RIPK3 and
MLKL (E), and using immunoprecipitation to analyze the necrosome (F). (G–J) MYC depletion suppresses tumor growth after treatment with birinapant (Bir)
and emricasan (Emri) in vivo. A total of 5 × 105 Molm13 cells were implanted subcutaneously into the flank of 6-wk-old nude mice. After 6 d, the mice were
treated with Bir (2 mg/kg) plus Emri (1 mg/kg) as indicated by intraperitoneal injection for 2 wk, and tumor growth is shown in G. Data are the means ± SEM,
n = 7 per treatment group, with *P < 0.05 and ***P < 0.001 at 19 d after the Molm13 cell injection according to a two-tailed Mann–Whitney test. Tumor-
bearing mice (H), excised tumors (I), and tumor masses (J) are shown. Data are presented as the mean values and individual data points from n = 7 mice, with
**P < 0.01, ***P < 0.001, and n.s. = nonsignificant according to the two-tailed Mann–Whitney test.
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Previously, MYC was shown to sensitize cells to TNF-α– and
RIP1-dependent apoptosis in fibroblasts and several types of
cancer cells, in part due to the decrease in levels of the FLIPL
protein (37, 38, 50, 65). Moreover, complex IIb formation and
subsequent apoptosis in HeLa cells, which lack RIPK3 expres-
sion, was slightly suppressed by MYC depletion (Figs. 2D and
3C) (50, 65). Interestingly, while MYC depletion increased
c-FLIPL expression in several cell lines—including HeLa,
HCT116, U2OS, and WI38 cells—it did not affect c-FLIPL ex-
pression in HT-29 and Molm13 cells (SI Appendix, Fig. S12). As
a result, TNF-α–induced complex IIb formation and apoptosis in
HT-29 were not affected by MYC depletion (Figs. 2 A and B and
3A). Based on these observations, the regulation of c-FLIPL and
apoptosis by MYC depends on the context and further studies
are needed to address these issues in the future.
Curiously, during necroptosis, RIPK3 activation leads to the
proteasomal degradation of MYC and thereby suppresses MYC/
MAX-dependent transcriptional programs, indicating a mutual in-
hibitory effect of RIPK3-mediated necroptosis and MYC. Although
the kinase activity of RIPK3 is required for MYC degradation, it is
not yet clear whether RIPK3 directly induces MYC degradation (SI
Appendix, Fig. S2). Given that increase of ubiquitination on MYC
during necroptosis, other proteins, such as E3 ubiquitin ligases,
might be involved to facilitate MYC degradation when RIPK3 is
activated by necroptotic stimuli, which requires further investiga-
tion. During necroptosis, RIPK3 phosphorylation by RIPK1 ap-
pears to induce MYC release form RIPK3 interaction, followed by
MYC degradation (SI Appendix, Fig. S7D). In this case, the disap-
pearance of MYC might contribute to necroptosis-induced in-
flammation in the late phase of cell death, as MYC is a well-known
antiinflammatory transcription factor (28, 66).
MYC is a master regulator of proliferation and metabolism in
cancer, and MYC-dependent modulation of these activities
might contribute to regulating necroptosis (62). Indeed, HT-29
cells completely depleted of MYC by the KO system exhibited a
slower proliferation rate than the control cells (SI Appendix, Fig.
S13 A and B). Nevertheless, transient depletion of MYC for 48 h
increased the sensitivity to necroptosis but had little effect on
proliferation, cellular ATP levels, and cell death, suggesting that
MYC might regulate necroptosis independent of its effects on
proliferation and metabolism (Fig. 1 and SI Appendix, Fig. S13
C–E). While we are unable to exclude the possible effects of the
transcriptional activities of MYC on necroptosis, MYC pre-
vented necroptotic cell death through a mechanism independent
of its transcriptional activity.
While necroptosis efficiently causes cell death in various types
of tissues, it often fails to induce cell death in most tumors due to a
lack of RIPK3 expression (25). In contrast, several cancer types,
such as leukemia, lymphoma, and colon cancer, contain intact
RIPK3 and undergo necroptosis (2, 54, 59, 67). Although the
contribution of necroptosis to early tumorigenesis is controversial
(68, 69), approaches designed to enhance necroptosis represent a
promising therapeutic strategy for established tumors (54–56).
The observation that MYC depletion dramatically enhances nec-
roptosis in the presence of birinapant and emricasan in vitro and
in vivo indicates that MYC might have been evolutionarily se-
lected by tumor cells to suppress necroptosis. As MYC negatively
regulates RIPK3, modulation of this pathway may be a therapeutic
strategy for treating cancer or inflammatory diseases.
Materials and Methods
Cell Viability Analysis and Flow Cytometry. For the analysis of cell viability, cells
were incubated with the CellTiter-Glo reagent and analyzed with a lumin-
ometer according to the manufacturer’s protocol (CellTiter-Glo Luminescent
Cell Viability Assay kit, G7571, Promega). For Annexin V and 7-AAD double
staining, prepared cells were harvested and washed with PBS, followed by
incubation with Annexin V-FITC (556547; BD Biosciences) and 7-AAD (00-
6993-50, eBioscience) in Annexin V Binding Buffer (51-66121E, BD
Biosciences) for 15 min according to the manufacturer’s protocol. For pro-
pidium iodide (PI) single staining, each leukemia cell line was harvested and
washed with PBS, followed by an incubation with PI for 15 min. Dead cells
were determined as the PI+ population, and viable cells were determined as
the PI− population by flow cytometry (BD Accrui C6, BD Biosciences). Data
were analyzed using BD Accuri C6 Plus software (BD Biosciences).
Immunofluorescence Analysis. HT-29 cells were plated on confocal dishes
(100350, SPL). After treatment with the indicated chemicals, the cells were
fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were
incubated with immunofluorescence blocking buffer (PBS with 3% BSA, 1%
saponin, and 1% Triton X-100) containing anti-MYC (1:100; 5605, Cell Sig-
naling) or anti-RIPK3 antibodies (1:50; 13526. Cell Signaling) overnight at 4 °C.
Samples were washed with PBS three times and then incubated with Alexa
Fluor 488 anti-rabbit (1:200; A-11008, Thermo Fisher Scientific) supple-
mented in immunofluorescence blocking buffer for 1 h. HeLa cells were
cultured on confocal dishes (100350, SPL). Cells were transfected with
HA-MYC- and RIPK3-GFP-expressing plasmids and then treated with the in-
dicated chemicals. After treatments, the cells were fixed with 4% parafor-
maldehyde for 10 min at room temperature and then permeabilized via
incubation with PBS containing 0.1% Triton-X 100. The samples were incu-
bated with PBS containing 2.5% BSA and anti-HA antibody (1:100; sc-7392,
Santa Cruz Biotechnology) for 2 h. The cells were washed with PBS three
times and then incubated with Alexa Fluor 594 anti-mouse (1:200; A-11005,
Thermo Fisher Scientific) for 1 h. DAPI was used to stain the nuclei. All
stained samples were analyzed with a confocal microscope (LSM 800,
Carl Zeiss).
Gel-Filtration Chromatography Analysis. HT-29 cells were transfected with a
nontargeting siRNA pool (siNT) and MYC siRNA pool (siMYC) for 48 h and
then treated with 20 ng/mL TNF-α, 2 μM BV6, and 30 μM zVAD-fmk for the
indicated times. Cells were collected from the seven 100-mm culture dishes
and lysed with 2.5 mL of lysis buffer containing 50 mM Tris·HCl (pH 7.5),
150 mM NaCl, 0.5% Triton X-100, and 1 mM EDTA, and lysates were injected
in an AKTA Prime Plus system and separated on a HiLoad 16/600 Superdex
200 column at a flow rate of 0.4 mL/min (GE Healthcare). Fractions of 2 mL
were collected, and samples were analyzed using Western blotting with the
indicated antibodies. Molecular weight markers were determined by gel-
filtration calibration kits (GE Healthcare).
MLKL Oligomerization. Cells were directly lysed in nonreducing 2× sample
buffer containing 100 nM Tris·HCl, 4% SDS, 20% glycerol, 20 mM EDTA, and
bromophenol blue without β-mercaptoethanol. For reducing conditions,
200 mM β-mercaptoethanol was added to nonreducing lysates. Both non-
reducing and reducing lysates were boiled for 10 min.
Xenograft Study. The subcutaneous tumor xenograft model was established
by resuspending ∼5 × 105 Molm13 cells expressing shRNAs in 50 μL of PBS
and 50 μL of Matrigel matrix (354234, BD Sciences) and subcutaneously in-
oculating the mixture into the flank of 6-wk-old female BALB/c nude mice
(Narabiotech). Six days after inoculation, the mice bearing xenograft tumors
were intraperitoneally injected with birinapant (2 mg/kg) plus emricasan
(1 mg/kg), as indicated in Fig. 7G. Nineteen days after inoculation, the mice
were killed and the tumor volumes and masses were measured using a
previously described method (70). All animal experiments related to the
subcutaneous tumor xenograft model were approved by the Institutional
Animal Care and Use Committee of the Laboratory Animal Research at
Yonsei University (IACUC-A-201703-174-02).
Data Availability. Major protocols, cell viability analysis and flow cytometry,
immunofluorescence analysis, gel-filtration chromatography analysis, MLKL
oligomerization, and xenograft study are described in Materials and Meth-
ods. See SI Appendix, SI Materials and Methods for a detailed description of
cell culture, plasmids and transfection, generation and validation of the
MYC KO cell lines, information of siRNA, shRNA, chemicals, and cell death
stimulation, immunoprecipitation and immunoblotting, cytoplasmic/nuclear
and soluble/insoluble fractionation, protein purification, in vitro binding and
kinase assays, qRT-PCR, RNA sequencing and GSEA, and statistics. RNA se-
quencing data have been deposited in the Gene Expression Omnimbus da-
tabase (accession no. GSE121149).
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